Comparing two surgical methods for ovarian cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of rectosigmoid resection versus seromuscular tumor shaving in patients with epithelial ovarian cancer that has metastasized to the rectosigmoid area. The study aims to determine which surgical approach leads to better outcomes in terms of complete tumor removal and overall patient survival. Participants will undergo one of the two surgical interventions, and their recovery and recurrence rates will be monitored. The trial is crucial as it addresses a common complication in advanced ovarian cancer treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Epithelial ovarian cancer
* Negative colonoscopy ( no mucosal involvement)
* Intraoperative confirmed serosal or seromuscular rectosigmoid infiltration
* ECOG \<3
* ASA \<3

Exclusion Criteria:

* Nonepithelial ovarian cancers
* Rectosigmoid mucosal infiltration
* Total or subtotal colectomy necessitating large bowel infiltrations
* ECOG \>2
* ASA \>2

Where it's running

• Cukurova University
  Adana, Turkey (Türkiye) Recruiting
• Cukurova University
  Adana, Turkey (Türkiye) Not yet recruiting

Study contacts

• Study coordinator: Ghanim Khatib, MD
• Email: ghanim.khatib@gmail.com
• Phone: +903223386060

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• VT-101 in Advanced Ovarian Cancer: early safety study in adults

  This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.

  Recruiting Phase 1 University of Iowa · Iowa City, Iowa · NCT07905677

• Torvutatug samrotecan plus bevacizumab as first-line maintenance in non-HRD advanced epithelial ovarian cancer

  This trial tests whether adding torvu-samrotecan to bevacizumab after standard chemotherapy helps people with non-HRD advanced epithelial ovarian cancer live longer without the cancer worsening compared with bevacizumab alone.

  Recruiting at 4 sites Phase 3 AstraZeneca · Tamarac, Florida and 219 other locations · NCT07851025

• Whole-body metabolic activity as a predictor of chemotherapy response in epithelial ovarian cancer

  This study tests whether whole-body metabolic activity can predict how well epithelial ovarian cancer responds to chemotherapy.

  Recruiting University of Tennessee Graduate School of Medicine · Knoxville, Tennessee · NCT07764133

• [68Ga]BED003 PET imaging to see fibroblast activity in selected cancers

  This study tests a PET imaging agent, [68Ga]BED003, to see how well it detects tumors in colorectal, gastric, pancreatic, ovarian, and invasive lobular breast cancers.

  Recruiting at 5 sites Phase 2 Blue Earth Diagnostics · Bergamo, Lombardy and 5 other locations · NCT07702292

• Dual-target CAR-NK Cells for Peritoneal Cancers of the Ovary, Fallopian Tube, or Pseudoperitoneal Disease

  This trial tests a dual-target CAR-NK cell therapy for people with recurrent or hard-to-treat epithelial ovarian, fallopian tube, or primary peritoneal cancer who express two or more specific tumor markers.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07617753

• Dual-Target CAR-NK Cells for Recurrent or Refractory Epithelial Ovarian Cancer

  This trial tests EB-DUALNK, a dual-target CAR-NK cell therapy, in adults with recurrent or refractory epithelial ovarian, fallopian tube, or peritoneal cancer to see if it can safely help the cancer shrink or stay controlled.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07589543

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.